Clinical Trial Update: Effect of Loratadine in Lymphangioleiomyomatosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing loratadine for lymphangioleiomyomatosis is listed with an unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Loratadine (Loratadine)

Snippet

Sponsor: Institut d'Investigació Biomèdica de Bellvitge | Conditions: Lymphangioleiomyomatosis | Phase 2 | Status: UNKNOWN